Opko Health Inc (OPK) Stock Price, Quote & News

Company Profile

OPKO Health, Inc., a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offer laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to...

Industry: Diagnostics & Research

Sector: Healthcare

Phone: 305 575 4100

Website: www.opko.com

Address:

4400 Biscayne Boulevard, Miami, United States

noYoav Feb. 24 at 2:35 AM

$OPK Hello, I entered this stock last Friday because the chart looked strong. Experiencing a 4% drop on the very next trading day definitely hurts. Could anyone share key information about the company or any potential upcoming catalysts?

1 · Reply

tymtested Feb. 24 at 12:43 AM

$OPK still buying. BULLISH

0 · Reply

Zerrat Feb. 23 at 11:05 PM

$OPK lol ceo purchase, stock buyback, new clicinal trials. Price heading to New history lows. Great job. Defying all financial theories but one: no cash flow and no hopes for cash flows. Lol

0 · Reply

tymtested Feb. 23 at 9:48 PM

$OPK ENTX & OPK 50/50 partners in development of long acting oral PTH tablet for hypoparathyroidism - expect to file IND by end of 2026... 10 bagger oncoming!! clinicals are progressing nicely with phase 3 upcoming.

0 · Reply

OldCarGuy Feb. 23 at 9:28 PM

$OPK Yeah, I can see them reporting on Thursday and watching the stock slip below a dollar on Friday. Then comes the talk of delisting…

0 · Reply

Mike18181 Feb. 23 at 9:11 PM

$OPK ADAM Logal ( CFO) to work part time at HR block doing tax returns.. I rather have a 2 year junior college kid with " marginable English " do my return for me ! 👦

0 · Reply

Mike18181 Feb. 23 at 4:41 PM

$OPK Opko to develope a Vaccine for clueless Management of public companies. Its in stage 3 clinical trials. 0️⃣

0 · Reply

Estimize Feb. 23 at 4:03 PM

Wall St is expecting -0.06 EPS for $OPK Q1 [Reporting 05/12 AMC] http://www.estimize.com/intro/opk?chart=historical&metric_name=eps&utm_con

0 · Reply

tradertrash Feb. 23 at 4:01 PM

$OPK announce a buyback year and a half, two years ago, it's been so long ive forgot how long now, stock price still in the crapper, these guys are useless

0 · Reply

Sierradude Feb. 23 at 2:23 PM

$OPK And after they buy back, watch them dilute it again....

0 · Reply

OPKO Health to Report Fourth Quarter 2025 Financial Results on February 26

Feb 4, 2026, 8:00 AM EST - 19 days ago

OPKO Health and Entera Bio Expand Partnership to Advance First-in-Class Oral Long Acting PTH Tablet for Patients with Hypoparathyroidism

Jan 27, 2026, 4:03 AM EST - 27 days ago

OPKO Health: Deeply Mispriced Ahead Of Major Catalysts

Jan 15, 2026, 5:45 AM EST - 5 weeks ago

OPKO Health, Inc. (OPK) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Jan 6, 2026, 4:11 PM EST - 6 weeks ago

OPKO Health to Participate in the 44th Annual J.P. Morgan Healthcare Conference

Nov 19, 2025, 4:05 PM EST - 3 months ago

OPKO Health to Participate in the Piper Sandler 37th Annual Healthcare Conference

Oct 29, 2025, 9:36 PM EDT - 4 months ago

OPKO Health, Inc. (OPK) Q3 2025 Earnings Call Transcript

Oct 29, 2025, 4:05 PM EDT - 4 months ago

OPKO Health Reports Third Quarter 2025 Business Highlights and Financial Results

Oct 22, 2025, 4:05 PM EDT - 4 months ago

OPKO Health to Report Third Quarter 2025 Financial Results on October 29

Sep 15, 2025, 8:30 AM EDT - 5 months ago

Labcorp Completes Acquisition of Select Assets of BioReference Health's Innovative Oncology and Related Clinical Testing Services Businesses

Jul 31, 2025, 9:19 PM EDT - 7 months ago

OPKO Health, Inc. (OPK) Q2 2025 Earnings Call Transcript

Jul 31, 2025, 4:05 PM EDT - 7 months ago

OPKO Health Reports Second Quarter 2025 Business Highlights and Financial Results

Jun 30, 2025, 8:01 AM EDT - 8 months ago

NextPlat Issues Interim CEO Update Shareholder Letter

NXPL

Jun 25, 2025, 11:00 AM EDT - 8 months ago

OPKO Health to Participate in the 3rd Annual Piper Sandler Virtual Obesity Symposium

May 15, 2025, 8:00 AM EDT - 10 months ago

OPKO Health to Participate in Two Upcoming Investor Conferences

Apr 30, 2025, 7:52 PM EDT - 10 months ago

OPKO Health, Inc. (OPK) Q1 2025 Earnings Call Transcript

Apr 4, 2025, 8:00 AM EDT - 11 months ago

OPKO Health Announces $100 Million Increase to its Existing Share Repurchase Program

Mar 17, 2025, 8:57 AM EDT - 1 year ago

OPKO and Entera partner to develop obesity pill

Mar 11, 2025, 7:00 AM EDT - 1 year ago

Labcorp Announces Acquisition of Select Assets of BioReference Health's Innovative Oncology and Related Clinical Testing Services Businesses

Feb 27, 2025, 7:12 PM EST - 1 year ago

OPKO Health, Inc. (OPK) Q4 2024 Earnings Call Transcript

Feb 27, 2025, 4:10 PM EST - 1 year ago

OPKO Health Reports Fourth Quarter 2024 Business Highlights and Financial Results

Jan 9, 2025, 11:45 AM EST - 1 year ago

OPKO Health to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Nov 18, 2024, 8:00 AM EST - 1 year ago

NextPlat to Showcase OPKO Healthcare Products at the 2024 China International Natural Health & Nutrition Expo

NXPL

Nov 14, 2024, 6:00 AM EST - 1 year ago

NextPlat Reports $49.8 Million in Consolidated Revenue for the Nine Months Ended September 30, 2024, Representing a 136% Increase Over 2023 Results

BABA NXPL

Nov 7, 2024, 8:30 PM EST - 1 year ago

OPKO Health, Inc. (OPK) Q3 2024 Earnings Conference Call Transcript

Oct 7, 2024, 8:00 AM EDT - 1 year ago

ModeX Therapeutics Secures $35 Million BARDA Supplement to Develop COVID Multispecific Antibodies and $16 Million to Initiate Influenza Program

Oct 7, 2024, 8:00 AM EDT - 1 year ago

NextPlat Secures Four-Year Extension of OPKO Healthcare E-Commerce Program in China and Agrees to the Expansion of the Program into Japan

NXPL

Sep 16, 2024, 7:30 AM EDT - 1 year ago

Labcorp Completes Acquisition of Select Assets of BioReference Health's Diagnostics Business from OPKO Health

Aug 7, 2024, 4:06 PM EDT - 1 year ago

OPKO Health Reports Second Quarter 2024 Business Highlights and Financial Results

Jul 17, 2024, 4:14 PM EDT - 1 year ago

OPKO Health and HealthCare Royalty Enter into $250 Million Note Purchase Agreement Secured by NGENLA's Profit Share Payments

May 31, 2024, 10:48 AM EDT - 1 year ago

OPKO Health to Participate in the Jefferies Global Healthcare Conference

May 7, 2024, 8:03 PM EDT - 1 year ago

OPKO Health, Inc. (OPK) Q1 2024 Earnings Call Transcript

May 7, 2024, 4:05 PM EDT - 1 year ago

OPKO Health Reports First Quarter 2024 Business Highlights and Financial Results

May 3, 2024, 8:00 AM EDT - 1 year ago

OPKO Health to Report First Quarter 2024 Financial Results on May 7, 2024

Mar 28, 2024, 8:00 AM EDT - 2 years ago

Labcorp Announces Acquisition of Select Assets of BioReference Health's Diagnostics Business

Mar 5, 2024, 8:52 AM EST - 2 years ago

AIDS Clinical Trial Group Presents Results from Phase 1 Study of ModeX Trispecific Antibody for the Treatment and Prevention of HIV

Feb 27, 2024, 8:08 PM EST - 2 years ago

OPKO Health, Inc. (OPK) Q4 2023 Earnings Call Transcript

Feb 27, 2024, 4:05 PM EST - 2 years ago

OPKO Health Reports Fourth Quarter 2023 Business Highlights and Financial Results

Feb 22, 2024, 4:05 PM EST - 2 years ago

OPKO Health to Report Fourth Quarter 2023 Financial Results on February 27, 2024

Jan 9, 2024, 4:05 PM EST - 2 years ago

OPKO Health Announces Closing of Private Offering of $230 Million Convertible Senior Notes Due 2029 including Full Exercise of Initial Purchaser's Option to Purchase Additional Notes

Jan 4, 2024, 11:31 PM EST - 2 years ago

OPKO Health Announces Pricing of Private Offering of $200 Million Convertible Senior Notes Due 2029

Jan 3, 2024, 5:05 PM EST - 2 years ago

OPKO Health Announces Private Offering of Convertible Senior Notes Due 2029

Nov 28, 2023, 7:00 AM EST - 2 years ago

BioReference Health and Prognos Health Collaborate to Advance Precision Medicine and Testing

Nov 7, 2023, 6:45 AM EST - 2 years ago

BioReference® Signs On as the First Laboratory to Use MSK-ACCESS® Powered with SOPHiA DDM™

SOPH

Nov 6, 2023, 7:32 PM EST - 2 years ago

OPKO Health, Inc. (OPK) Q3 2023 Earnings Call Transcript

Nov 6, 2023, 4:05 PM EST - 2 years ago

OPKO Health Reports Third Quarter 2023 Business Highlights and Financial Results

Nov 2, 2023, 10:00 AM EDT - 2 years ago

New Clinical Data on OPKO Health's RAYALDEE® (ER Calcifediol) Presented at Kidney Week 2023

Oct 31, 2023, 8:00 AM EDT - 2 years ago

OPKO Health to Report Third Quarter 2023 Financial Results on November 6, 2023

Oct 25, 2023, 4:25 PM EDT - 2 years ago

OPKO Health to Present New Clinical Data on Rayaldee (ER Calcifediol) at Kidney Week 2023

Oct 20, 2023, 1:30 PM EDT - 2 years ago

OPKO Health: FDA Approval To Save The Company

noYoav Feb. 24 at 2:35 AM

1 · Reply

tymtested Feb. 24 at 12:43 AM

$OPK still buying. BULLISH

0 · Reply

Zerrat Feb. 23 at 11:05 PM

$OPK lol ceo purchase, stock buyback, new clicinal trials. Price heading to New history lows. Great job. Defying all financial theories but one: no cash flow and no hopes for cash flows. Lol

0 · Reply

tymtested Feb. 23 at 9:48 PM

0 · Reply

OldCarGuy Feb. 23 at 9:28 PM

$OPK Yeah, I can see them reporting on Thursday and watching the stock slip below a dollar on Friday. Then comes the talk of delisting…

0 · Reply

Mike18181 Feb. 23 at 9:11 PM

$OPK ADAM Logal ( CFO) to work part time at HR block doing tax returns.. I rather have a 2 year junior college kid with " marginable English " do my return for me ! 👦

0 · Reply

Mike18181 Feb. 23 at 4:41 PM

$OPK Opko to develope a Vaccine for clueless Management of public companies. Its in stage 3 clinical trials. 0️⃣

0 · Reply

Estimize Feb. 23 at 4:03 PM

Wall St is expecting -0.06 EPS for $OPK Q1 [Reporting 05/12 AMC] http://www.estimize.com/intro/opk?chart=historical&metric_name=eps&utm_con

0 · Reply

tradertrash Feb. 23 at 4:01 PM

$OPK announce a buyback year and a half, two years ago, it's been so long ive forgot how long now, stock price still in the crapper, these guys are useless

0 · Reply

Sierradude Feb. 23 at 2:23 PM

$OPK And after they buy back, watch them dilute it again....

0 · Reply

Mike18181 Feb. 20 at 12:38 AM

$OPK If free cash flow existed , it would take a long while to fix this. The stock is basically wiped out from accumulated losses since 2006. These are FACTS. ***Bring in any top Finance person and this is true. They will tell the company is run badly since 2006. The stock will not go up. Why have a buy back ? Make the EPS positive. " opko is run like a piss poor 3rd world country "

0 · Reply

tymtested Feb. 19 at 5:49 PM

$OPK market is playing straight into the stock buyback program!!

1 · Reply

tymtested Feb. 19 at 5:46 PM

$OPK Im still buying!!

1 · Reply

tymtested Feb. 19 at 5:45 PM

$OPK PFE equity rating is 3.5 and OPKO equity rating is 8!!!!! Analysts are BULLISH on OPKO! Huge BUYING opportunity!!

0 · Reply

Sierradude Feb. 19 at 4:38 PM

$OPK how low can it go? nobody knows when its Opko!

1 · Reply

Liorkd Feb. 19 at 4:17 PM

$OPK 4th quarter should be profitable Opko will record about 90 million usd from the last labcorp deal this quarter Also bio reference should be profitable And usually 4th quarter is strong all over Easy beat

0 · Reply

Estimize Feb. 19 at 4:03 PM

Wall St is expecting -0.07 EPS for $OPK Q4 [Reporting 02/26 AMC] http://www.estimize.com/intro/opk?chart=historical&metric_name=eps&utm_con

0 · Reply

Mactoast Feb. 19 at 3:45 PM

$OPK What a shitty chart! 3 month, 1 year, 5 year, 10 year. Take your pick. I’m on the 10 year plan with no hope or future prospects!

0 · Reply

Mike18181 Feb. 19 at 3:45 PM

$OPK Nexplatt and opko revenue is less than 1k

0 · Reply

Mike18181 Feb. 19 at 3:44 PM

$OPK " building shareholder value at $ 1.19 ...🥰

0 · Reply

bulmar Feb. 19 at 3:35 PM

$OPK This should be 10 bucks because the billionaire Frost owns it. He buys shares of his companies all the time and they just go down. Go back to sleep old man.

0 · Reply

Brasil07 Feb. 18 at 8:37 PM

$OPK if they wait, between 15 days everyone shall buy under 1

0 · Reply

Market Cap	921.24M
Revenue (ttm)	713.14M
Net Income (ttm)	-53.22M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-7.46%
Debt to Equity Ratio	0.19

Volume	2,133,700
Avg Vol	3,305,974
Day's Range	N/A - N/A
Shares Out	767.70M
Stochastic %K	0%
Beta	1.47
Analysts	Strong Sell
Price Target	$2.57